MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

Coverage is limited to molecular DNA/RNA assays ordered by a board-certified or board-eligible dermatopathologist for primary (non-metastatic, non-re-excision) cutaneous melanocytic lesions when diagnosis remains equivocal after standard histopathology and ancillary testing, the specimen contains a representative suspicious area, and results could affect management (e.g., re-excision or sentinel node biopsy). Tests must not have been previously performed on the same lesion and must be validated for the intended-use population with demonstrated analytical validity, clinical validity, clinical utility, and a MolDX technical assessment. Tests or situations that do not meet all these requirements are not covered.

"The test is ordered by a board-certified or board-eligible dermatopathologist."

Sign up to see full coverage criteria, indications, and limitations.